BioSpace News Archive

Virbac announces the breakthrough drug STELFONTA ® (tigilanol tiglate injection) that has been approved by the U.S. Food and Drug Administration (FDA) as a non-surgical alternative for treating canine mast cell tumors in dogs, is now available in veterinary clinics throughout the United States .

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished dose products today announced its financial results for the three and six months ended June 30, 2021, a period of ongoing progress in establishing itself as an international pharmaceutical company specializing in cannabis.

NTT Research, Inc., a division of NTT (TYO:9432), today announced that members of its Cryptography & Information Security (CIS) Lab authored or co-authored 18 papers that are being delivered at Crypto 2021, one of the leading international conferences on cryptologic research.

Lantern Pharma (NASDAQ: LTRN), today announced that Lantern Pharma’s abstract titled ‘LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects’ has been accepted as a virtual poster at the upcoming AACR Virtual Special Conference on Pancreatic Cancer being held on September 29-30, 2021.

Oramed Pharmaceuticals Inc. today announced that Diabetes, Obesity, and Metabolism, has published an original article titled “Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes mellitus

The Pharmaceutical Industry Labor-Management Association released an update to its first-of-its-kind report on the economic impact of the long-standing partnership between skilled craft unions and the biopharmaceutical industry in New York and 13 other states.

Carrick Therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2- advanced breast cancer and samuraciclib for the treatment of locally advanced or metastatic triple negative breast cancer.

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, reported financial results and provided a business update for the quarter ended June 30, 2021.

Castellum, Inc. (OTC: ONOV) announces that it has acquired Specialty Systems, Inc. (SSI) a Toms River, New Jersey based government contractor.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced initiation of the first cohort of its Phase 1b/2 TRIDENT-2 combination study of lead investigational drug repotrectinib.